Study Demonstrating Globus Medical’s Expandable Technology Improves Lordosis and Reduces Subsidence Awarded Best Paper at S...
October 04 2018 - 4:30PM
Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal
solutions company, announced today that a recent clinical study
evaluating static versus expandable lateral lumbar interbody fusion
devices was awarded best paper at the Society for Minimally
Invasive Spine Surgery (SMISS) Annual Forum held last month.
The study, led by Dr. Richard Frisch, an orthopedic surgeon at
Southeastern Spine Institute, compared clinical and radiographic
outcomes of sixty-four patients who underwent minimally invasive
lateral lumber interbody fusion (LLIF) for symptomatic degenerative
disc disease. At one year postoperative follow up, patients treated
with Globus Medical’s expandable technology experienced
significantly greater segmental lordosis and a significantly lower
subsidence rate than those in the static group, based on
radiographic evidence. Both the expandable and static
spacer groups reported similar improvements in back pain scores
with no significant differences in clinical outcomes.
“Subsidence of interbody spacers is a clinical concern due to
loss of disc height and foraminal height, and the recurrence of
symptoms that may result in revision surgery,” said Dr. Frisch.
“The preliminary results of this study suggest that expandable
lateral interbody spacers offer important clinical advantages by
increasing and maintaining segmental lordosis while potentially
decreasing the risk of endplate damage and subsidence.”
Andrew Iott, Senior Vice President of Global Product
Development, commented, “Globus Medical would like to congratulate
Dr. Frisch on receiving this best paper award at SMISS. We are
proud to have sponsored this important research demonstrating the
benefits of expandable interbody spacers. As the market leader
in expandable interbody technologies, Globus is committed
to developing next generation implants that provide
innovative solutions to maximize lordosis and help address sagittal
imbalance.”
To access the study and learn more about Globus Medical’s
portfolio of lateral expandable interbody spacers, visit
www.GlobusMedical.com/LLIF
About Globus Medical, Inc.Globus Medical, Inc.
is a leading musculoskeletal solutions company based in Audubon,
PA. The company was founded in 2003 by an experienced team of
professionals with a shared vision to create products that enable
surgeons to promote healing in patients with musculoskeletal
disorders. Additional information can be accessed
at http://www.globusmedical.com.
Safe Harbor StatementsAll statements included
in this press release other than statements of historical fact are
forward-looking statements and may be identified by their use of
words such as “believe,” “may,” “might,” “could,” “will,” “aim,”
“estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan”
and other similar terms. These forward-looking statements are based
on our current assumptions, expectations and estimates of future
events and trends. Forward-looking statements are only predictions
and are subject to many risks, uncertainties and other factors that
may affect our businesses and operations and could cause actual
results to differ materially from those predicted. These risks and
uncertainties include, but are not limited to, factors affecting
our quarterly results, our ability to manage our growth, our
ability to sustain our profitability, demand for our products, our
ability to compete successfully (including without limitation our
ability to convince surgeons to use our products and our ability to
attract and retain sales and other personnel), our ability to
rapidly develop and introduce new products, our ability to develop
and execute on successful business strategies, our ability to
comply with changing laws and regulations that are applicable to
our businesses, our ability to safeguard our intellectual property,
our success in defending legal proceedings brought against us,
trends in the medical device industry, general economic conditions,
and other risks. For a discussion of these and other risks,
uncertainties and other factors that could affect our results, you
should refer to the disclosure contained in our most recent annual
report on Form 10-K filed with the Securities and Exchange
Commission, including the sections labeled “Risk Factors” and
“Cautionary Note Concerning Forward-Looking Statements,” and in our
Forms 10-Q, Forms 8-K and other filings with the Securities and
Exchange Commission. These documents are available at www.sec.gov.
Moreover, we operate in an evolving environment. New risk factors
and uncertainties emerge from time to time and it is not possible
for us to predict all risk factors and uncertainties, nor can we
assess the impact of all factors on its business or the extent to
which any factor, or combination of factors, may cause actual
results to differ materially from those contained in any
forward-looking statements. Given these risks and uncertainties,
readers are cautioned not to place undue reliance on any
forward-looking statements. Forward-looking statements contained in
this press release speak only as of the date of this press release.
We undertake no obligation to update any forward-looking statements
as a result of new information, events or circumstances or other
factors arising or coming to our attention after the date
hereof.
Contact:Brian KearnsVice President, Business
Development and Investor RelationsPhone: (610) 930-1800Email:
investors@globusmedical.comwww.globusmedical.com
Globus Medical (NYSE:GMED)
Historical Stock Chart
From Mar 2024 to Apr 2024
Globus Medical (NYSE:GMED)
Historical Stock Chart
From Apr 2023 to Apr 2024